Agenda

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.

Faculty

Lori Alexander, MSHS, RD, CCRC, CLS, FNLA

Site Manager    
St. Johns Center for Clinical Research     
Ponte Vedra, FL

Alan S. Brown, MD, FNLA

Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL
Diplomate, American Board of Clinical Lipidology

Sanford A. Carimi, MD, FNLA

President, Midwest Lipid Association
Director, Unity Point-Meriter Lipid Clinic
Monona, WI
Diplomate, American Board of Clinical Lipidology

Mary Katherine Cheeley, PharmD, BCPS, CLS

Clinical Pharmacist
Grady Health System
Atlanta, GA

Dave L. Dixon, PharmD, BCPS, CDE, CLS, FNLA

Associate Professor, Ambulatory Care
Vice-Chair of Clinical Services
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University
School of Pharmacy
Richmond, VA

Sergio Fazio, MD, PhD, FNLA

Professor of Medicine Director of Preventive Cardiology
Oregon Health and Science University Portland, OR
Diplomate, American Board of Clinical Lipidology

John R. Guyton, MD, FNLA

Professor of Medicine
Assistant Professor of Pathology
Department of Medicine
Duke University School of Medicine
Durham, NC
Diplomate, American Board of Clinical Lipidology

Susan Halli Demeter, RN, DNP, CFNP, CLS

Instructor of Medicine Mayo Clinic
Scottsdale, AZ  
Faculty Associate
Arizona State University
Phoenix, AZ

Benjamin M. Helm, MS, CGC

Indiana University
School of Medicine
Indianapolis, IN

Ann Liebeskind, MD

Founder, Complex Lipids Clinic
Mobile Health Team
Neenah & Wauwautosa, WI 
Diplomate, American Board of Clinical Lipidology

Kellie H. McLain, ANP-BC, CLS

Medical University of South Carolina
Mt. Pleasant, SC

Michael F. Murray, MD

Associate Geneticist, Brigham and Women's Hospital
Instructor in Medicine, Harvard Medical School
Brigham and Women's Hospital
Department of Medicine- Genetics
Boston, MA

Khurram Nasir, MD, PhD

Research Director, Center for Prevention and Wellness
Director, High-Risk Cardiovascular Disease Clinic
Baptist Health South Florida
Miami, FL

Katherine S. Rhodes, PhD, RD

Nutrition Services
University of Michigan Cardiovascular Medicine
Ann Arbor, MI

Amy C. Sturm, MS, LGC

Professor & Director of Cardiovascular Genomic Counseling
Genomic Medicine Institute
Geisinger Health System
Lewis Center, OH

Beth A. Taylor, PhD

Associate Professor of Kinesiology
University of Connecticut
Storrs, CT
Director of Exercise Physiology Research
Hartford Hospital
Hartford, CT

Salim S. Virani, MD, PhD

Assistant Professor
Medicine-Atherosclerosis & Lipoprotein
Medicine - Cardiology
Baylor College of Medicine
Houston, TX

Kaye-Eileen Willard, MD, FNLA

Chief of Department of Medicine
Medical Director, Chronic Disease Management
Wheaton Franciscan Healthcare, All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology

Lauren Williams, MCN, RD, LD

Clinical Dietitian II
REACH/Endocrinology Clinic
Cook Children’s Medical Center
Fort Worth, TX

Peter W.F. Wilson, MD, FNLA

Professor of Medicine
Division of Cardiology
Emory University School of Medicine
Professor of Public Health
Rollins School of Public Health
Director, Epidemiology and Genomic Medicine
Atlanta VA Medical Center
Atlanta, GA

Program Planners

Anne C. Goldberg, MD, FACP, FNLA

Committee Co-Chair
President, Foundation of the NLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology

James A. Underberg, MD, MS, FNLA

Committee Co-Chair
President, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology

Sanford A. Carimi, MD, FNLA

President, Midwest Lipid Association
Planning Committee Member
Director, Unity Point-Meriter Lipid Clinic
Monona, WI
Diplomate, American Board of Clinical Lipidology

Deborah S. Croy, DNP, ANP, CLS, FNLA

President, Southeast Lipid Association
Planning Committee Member
Nurse Practitioner
Bland County Medical Clinic
Bastian, VA

Ira J. Goldberg, MD, FNLA

Planning Committee Member
Clarissa and Edgar Bronfman, Jr. Professor
Director, Division of Endocrinology, Diabetes and Metabolism
NYU Langone Medical Center
New York, NY

Vanessa L. Hurta, NP, MS, CLS

Planning Committee Member
Bellevue Hospital Center Lipid Clinic
New York, NY

Elizabeth Jackson, MSN, ACNS-BC, CLS, FNLA

Planning Committee Member
Cardio Texas
St. David's Medical Center
Austin, TX

Peter H. Jones, MD, FNLA

Planning Committee Member
Associate Professor of Medicine Co-director,
Lipid Metabolism and Atherosclerosis Clinic Center for Cardiovascular Disease Prevention Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX
Diplomate, Amercian Board of Clinical Lipidology

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

Planning Committee Member
Wellness Center Director
Clinical Assistant Professor
Idaho State University
Pocatello, ID

Pamela B. Morris, MD, FNLA

Planning Committee Member
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Mt. Pleasant, SC
Diplomate, American Board of Clinical Lipidology

Joseph J. Saseen, PharmD, CLS, FNLA

Planning Committee Member
Professor
Clinical Pharmacy & Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

Daniel E. Soffer, MD, FNLA

Planning Committee Member
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology

Nathan O. Stitziel, MD, PhD

Planning Committee Member
Assistant Professor of Medicine and Genetics
Washington University School of Medicine
Saint Louis, MO

Featured Sessions

Accreditation

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity
Application, Knowledge

Educational Objectives
At the conclusion of this activity, all participants should be able to:

• Discuss strategies to improve the knowledge, skills or performance of the healthcare team;

Session I:  The Value and Impact of Genetic Testing for FH: From Genetic Counselor to Patient and Back Again

• Explain the benefits of genetic testing in Familial Hypercholesterolemia (FH) screening;
• Recognize the importance of genomics in the identification of patients with FH;
• Discuss the role of genetic counseling in FH;

Session II:  PCSK9 Inhibitors- What Can Lipidologists Expect for the Future

• Interpret important recent clinical trial research and its impact on daily clinical practice;
• Assess the implications of ongoing lipid treatment outcomes trials for the future clinical management of patients with dyslipidemia;
• Discuss emerging therapeutic targets for the management of dyslipidemia;

Session III:  Chylomicronemia Syndrome

• Describe the prevalence, risk, and complications of chylomicronemia syndrome;
• Assess the impact of diet in the management of chylomicronemia;
• Analyze complex cases for health professionals seeing patients with chylomicronemia syndrome;

Session IV: Now You See It, Now You Don’t: Great Debates on the Role of Calcium Scoring in Clinical Decision Making in Dyslipidemia

• Compare and contrast appropriate treatment options for patients based on calcium scoring;

Mini Session

• Discuss the association between the gut microbiome and its possible influence on the development of CVD;

Session V: LDL and Lp(a) Measurement Potential Pitfalls and Problems

• Explore the developing measures that will guide the diagnosis and treatment of lipid disorders in the future;
• Describe treatment options for patients with high Lp(a);

Session VI:  Coffee and Cases

• Analyze lipid cases for health professionals seeing patients with complex disorders;

• Implement strategies for the entire patient care team to manage complex cases;

Session VII: Statin Related Muscle Necrosis

• Implement appropriate assessment and management techniques for muscle-related adverse events associated with lipid-altering drugs.

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 14 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement

Session I- Universal Activity Number 0624-0000-17-033-L01-P (Knowledge)
This Activity has been approved for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session II- Universal Activity Number 0624-0000-17-034-L01-P (Knowledge)
This Activity has been approved for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session III- Universal Activity Number 0624-0000-17-035-L01-P (Knowledge)
This Activity has been approved for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session IV – Universal Activity Number 0624-0000-17-036-L01-P (Knowledge)
This Activity has been approved for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Mini Session- Universal Activity Number 0624-0000-17-037-L01-P (Knowledge)
This Activity has been approved for .75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education

Session V– Universal Activity Number 0624-0000-17-038-L01-P (Knowledge)
This Activity has been approved for 2.00 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0624-0000-17-039-L01-P (Application)
This Activity has been approved for 1.50 contact hour(s) (.150 CEUs) of the Accreditation Council for Pharmacy Education

Session VII – Universal Activity Number 0624-0000-17-040-L01-P (Knowledge)
This Activity has been approved for 2.00 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 13.9 contact hours.
Session I- 2.1 credits; Session II- 2.2 credits; Session III- 2.1 credits; Session IV- 1.6 credits; Mini Session- .6 credits; Session V- 2.0 credits; Session VI- 1.8 credits; Session VII- 2.9 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

Commercial Support:
Full notification of commercial support will be provided in the activity syllabus.

Pre-Conference Courses

Are you new to Lipidology or just looking to brush up on the changing information coming out in the field? Attend one of our Pre-Conference courses taught by Experts in the area of Lipidology:

The NLA's Lipid Academy provides a comprehensive, in-depth indoctrination to lipid science and is open to all health care professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive Lipid Academy course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the Annual Scientific Forum and other advanced lipid training.

The NLA’s Masters in Lipidology Course is an intensive 2-day training course offers an in-depth review of the core curriculum in Clinical Lipidology for health care professionals who desire to practice at an advanced level within the field. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.

Abstracts

Abstracts Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Foundation Event

Get Down with Dr. Alan Brown's Band, This End Up

Saturday, August 12, 2017
7:00 – 9:00 PM
$70/person

Join us onsite at the JW Marriott for an evening packed with music, food, and fun. Support the Foundation of the National Lipid Association (FNLA), while enjoying today’s most popular songs, delicious apps, and tasty drinks with colleagues and friends. FNLA board member Dr. Alan Brown and his band, This End Up, will provide the tunes for the evening! After a full day of sessions, what better way to unwind!

Symposia

CME/CE Dinner Symposium
Friday, August 11th
7:00 – 9:00pm

Optimizing Cardiovascular Risk Reduction in High-Risk Patients Through Lipid Management

The Annenberg Center for Health Sciences at Eisenhower and the National Lipid Association (NLA) present Optimizing Cardiovascular Risk Reduction in High-Risk Patients Through Lipid Management, a live, 1.5-hour, CME-certified symposium presented by 2 experts in the field, Peter H. Jones, MD, FNLA, and Joseph J. Saseen, PharmD, CLS, FNLA.

The goal of the symposium is to apply evolving evidence concerning PCSK9 inhibitors to the real-world management of 4 patients with cardiac risk factors. Both faculty will provide their own experiences and commentary for each case, which, with extensive opportunity for questions by attendees, is sure to foster a lively and interactive discussion.

Presenters

Peter H. Jones, MD, FNLA
Associate Professor of Medicine Co-director,
Lipid Metabolism and Atherosclerosis Clinic Center for Cardiovascular Disease Prevention Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX
Diplomate, Amercian Board of Clinical Lipidology

Joseph J. Saseen, PharmD, CLS, FNLA
Professor
Clinical Pharmacy & Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

Hosted by Annenberg Center for Health Sciences at Eisenhower

CME/CE Breakfast Symposium
Saturday, August 12th
6:30 – 7:50am

SEVERE/RESISTANT HYPERCHOLESTEROLEMIA: Clinical Trials, Lessons Learned, and Outcomes Explored

Certain populations are at excessively high risk for major adverse cardiovascular events, including those with clinically evident atherosclerotic cardiovascular disease (ASCVD), defined as history of myocardial infarction, non-hemorrhagic stroke, or systemic peripheral artery disease. Other groups at higher risk include those with familial hypercholesterolemia, diabetes mellitus, or metabolic syndrome. Since hypercholesterolemia is a major driver of ASCVD, lipid-lowering therapies (chiefly with statins) are the primary treatment to reduce low-density lipoprotein cholesterol (LDL-C) and CVD risk. Unfortunately, intensive statin therapy lowers CVD risk only by about 50%, leaving patients at high residual CVD risk with no good options to reduce it. This major clinical gap may be in part addressed by PCSK9 inhibitors, which have been shown to produce robust LDL-C reduction (by ~60%) with statins and improve clinical outcomes in ASCVD patients.

Presenters

Alan S. Brown, MD, FACC, FAHA, FNLA
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL

James A. Underberg, MD, MS, FNLA
President, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology

Hosted by Rockpointe

Expert Theaters

Honors and Awards Ceremony

Honors and Awards Ceremony Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Mentoring Reception

Mentors and Mentees Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Mobile App

Coming soon

Social Media

Be part of the conversation and get the latest news and announcements from the Fall CLU. Follow the NLA on Twitter, Instagram, LinkedIn, and Facebook. Use the hashtag #NLAIndy when posting about the meeting.

Support Recognition

American Board of Clinical Lipidology (ABCL)
The ABCL is an independent physician-certifying organization offering the highest benchmark of professional competency in Clinical Lipidology. Enhance your professional stature and credibility in the field, and demonstrate your commitment to the highest standards of patient care. The program is open to licensed physicians in the US and Canada.
www.lipidboard.org

Accreditation Council for Clinical Lipidology (ACCL)
The ACCL offers the Clinical Lipid Specialist (CLS) certification program to licensed physicians, nurses, nurse practitioners, physician assistants, pharmacists, registered dietitian/nutritionists, clinical exercise physiologists and other healthcare professionals who meet qualifying criteria. The CLS program certifies and validates one's professional credentials to provide specialized care to patients with dyslipidemia and related cardiometabolic conditions.
www.lipidspecialist.org

Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The company has a diversified commercial portfolio of rare disease therapies which includes MYALEPT® and JUXTAPID®. Aegerion’s parent company, Novelion Therapeutics, seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion is currently developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. 
www.novelion.com

Akcea Therapeutics, a Subsidiary of Ionis Pharmaceuticals, Inc.
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is a development and commercialization company focused on transforming serious cardiometabolic lipid disorders. Akcea’s portfolio spans multiple targets and disease states, including both rare and more common lipid disorders, using advanced RNA-targeted antisense therapeutics.
www.akceatx.com

Alexion
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders, including lysosomal acid lipase deficiency (LAL-D). Learn more at www.alexion.com 

Amarin Pharma Inc.
www.amarincorp.com

Ambry Genetics
Ambry Genetics is a privately-held healthcare company with the most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases. Since 1999, Ambry has tested approximately half a million patient samples benefiting 90% of all U.S. patients covered by public and private insurers. Ambry’s hereditary cardiovascular testing menu includes multi-gene panels and single gene testing for inherited arrhythmias, cardiomyopathies, aortic aneurysms/dissections, Marfan syndrome, Ehlers-Danlos syndromes, and familial hypercholesterolemia. Establishing a molecular diagnosis for inherited cardiovascular conditions can be life-saving; genetic test results can direct and improve patient treatment and management, and can also target surveillance for cardiovascular complications.

Ambry continues to be a leader in diagnostic solutions by offering options that fit to your patient: single genes testing, multi-gene panels of varying sizes, reflex/tiered panels, and whole exome sequencing.
www.ambrygen.com

Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com

Boston Heart Diagnostics
Boston Heart Diagnostics is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve heart health. Boston Heart looks beyond the “good” and “bad” cholesterol assessment that conventional labs provide to give a more complete picture of heart health.
www.BostonHeartDiagnostics.com

Kastle Therapeutics
Our Mission is to serve patients who have significant unmet medical needs and are underserved. To solve challenges for therapeutic developers and manufacturers. To support quality of care for patients with severe diseases.
www.kastletherapeutics.com

Kaneka Pharma America, LLC
www.kaneka.com

Kowa Pharmaceuticals America, Inc.
Established in 2008, Kowa Pharmaceuticals America, Inc., is committed to developing and delivering safe, effective solutions in the field of cardiometabolic therapeutics. We do this by maintaining high ethical and professional standards--and it all starts with people. By empowering our employees to live this mission, we can create a healthier vision for the future. 
www.kowapharma.com

MotherToBaby Pregnancy Studies
MotherToBaby is the nation’s leading authority and most trusted source of evidence-based information on the safety of medications and other exposures during pregnancy and while breastfeeding. Our free teratogen information service is available to healthcare professionals and the general public.

MotherToBaby also conducts state‐of‐the‐art observational research on the safety of medications and vaccines in pregnancy which allows us to help moms and healthcare providers make informed treatment decisions. MotherToBaby Pregnancy Studies, conducted by the Organization of Teratology Information Specialists (OTIS), is currently evaluating the effects of ASCVD and FH along with the medications used to treat these diseases during pregnancy. Please visit mothertobaby.org to learn more.

Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health. 
Visit 4myheart.com and QuestDiagnostics.com

Retrophin
Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
www.retrophin.com

Sanofi Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

VAP Diagnostics Laboratory
VAP Diagnostics Lab is an independent reference laboratory focused solely on the comprehensive VAP®+ Lipid Panel and related cardiometabolic test panels. Using direct (not estimated) measurement, VAP+ identifies cholesterol, triglyceride and genetic lipid disorders, enabling health care professionals to accurately stratify cardiovascular risk and recommend personalized treatment strategies to improve health outcomes. Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines.
www.vapdiagnostics.com

Virtual Exhibit Hall

Virtual Exhibit Hall Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Industry Council

Industry Council coming soon...

Media Partners

JW Marriott

JW Marriott Indianapolis
10 South West Street
Indianapolis, IN 46204
Meeting Room Rate: $189/night plus tax

For reservations click here or call 866-704-6162 and ask for the National Lipid Association room block. Reserve your room early to get a discounted rate.

Recently named as the 25th best hotel in the world and number one in the Midwest by Conde Nast, JW Indy is one of five Marriott Place hotels in downtown Indianapolis. We are also home to Indy’s best Italian restaurant by Thrillist.com, Osteria Pronto. In addition, our enclosed skywalk system provides business and leisure travelers easy access to top area attractions.

Travel Information:
Book your airfare on Delta and receive up to 5% off your flight to Indianapolis. Book on delta.com and enter NMQKW in the offer code box when searching for your flight. Discount is applicable for travel to and from Indianapolis August 7-16, 2018.

Local Attractions

While in Indianapolis make time to visit....

Indianapolis Motor Speedway Museum

The Indianapolis Motor Speedway has been around since 1909, so this epic track has seen more than 100 races speed by. The 30,000-square-foot museum came about 50 years afterward, featuring about 75 cars and even a theater that shows Indy 500 footage throughout the years. Visitors have the choice to see the complex by purchasing race tickets, visiting the museum or taking the very popular (and comprehensive) grounds tour.

The Central Canal

The Central Canal, which also goes by the name Indy Canal Walk, was born in the 1840s when the Indiana state government was trying to bring more commerce to the city. But soon after, the state found itself bankrupt and the plans for a 296-mile waterway were shelved. Today, the Central Canal is a 3-mile loop that flows by the Indiana State Museum, Victory Field, the Indianapolis Zoo and the 250-acre White River State Park, among other popular attractions. You can walk alongside the canal or book a segway tour, but you can also hire a gondolier or rent a pedal boat or kayak.

Indianapolis Museum of Art

Spread out across 152 acres and featuring more than 54,000 works of art spanning 5,000 years, the Indianapolis Museum of Art is an impressive institution. It's also among the 10 largest art museums in the U.S. Superlatives aside, what visitors love most about IMA is its variety. Not only does it offer Neoimpressionist paintings (like Georges Seurat), contemporary art and Chinese ceramics, but it also boasts one of the largest contemporary art parks in the U.S. — The Virginia B. Fairbanks Art & Nature Park: 100 Acres.

Indiana War Memorial

Considered an Indiana landmark, the Indiana War Memorial comprises two museums, three parks and 24 acres of monuments, statues, sculptures and fountains. So, if you're a fan of the National Mall in Washington, D.C., you'll likely enjoy spending a few hours here. In fact, Indianapolis is second only to D.C. in acreage and number of monuments dedicated to veterans.

Late Breakers

Late Breaker Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Expert Theater

We are currently sold out of Expert Theater slots for the 2017 Fall Clinical Lipid Update. Please contact Exhibits@Lipid.org to learn more about additional non-CME programming opportunities at this conference.

CME Symposia

Please contact AResheidat@lipid.org to learn more about our symposia opportunities.

Exhibit in Indianapolis

Lipid Bucks: Lipid Bucks can be applied on the checkout page.

Registration: Registration and payment must be received no later than August 11, 2017. After this date, meeting materials and name badge cannot be guaranteed.

By registering for the 2017 NLA Fall Clinical Lipid Update, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By allowing an exhibitor to scan the conference badge, attendee understands, agrees and consents to the sharing of attendee’s contact information with the company that scanned the conference badge.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than July 11, 2017. This includes social events and guest fees. There will be a $100 fee for all cancellations. There will be no refunds if cancelling within 30 days of the start of the meeting date.